Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Erlotinib Hydrochloride

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Erlotinib (Tarceva®), 150mg/day p.o during 6 months.

Erlotinib (Tarceva®)

Enrique Martinez, Dr.

Nuria Viñolas, Dr.

Francesc Casas, Dr.

Alejandro De la Torre, Dr.

Ana Mª Perez Casas, Dr.

Julian Minguez, Dr.

Enrique Martínez, Dr.

A phase II, multicenter, randomized trial of 3D Radiotherapy versus 3D Radiotherapy and erlotinib (Tarceva®) in patients with localized-unresectable (IA-IIIB) non-small cell lung cancer non susceptible for chemotherapy treatment, to compare safety and toxicity profile, and the progression-free survival in both arms of treatment (3D Radiotherapy versus 3D Radiotherapy + erlotinib) in patients who have not received previous chemotherapy.

Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer

Phase II Randomized Trial of 3D Radiotherapy Versus the Combination of 3D Radiotherapy and Erlotinib (Tarceva®) in Patients With Localized-Unresectable Non-Small Cell Lung Cancer Non Susceptible for Chemotherapy Treatment.

Dr. Enrique Martínez López

Hospital of Navarra

Symptoms and General Pathology

Neoplasm Metastasis

Disease Progression

Erlotinib (TARCEVA®)

Myungju Ahn, Ph.D., M.D.

Newly developed or progressive brain metastasis during erlotinib treatment is considered progressive disease requiring change of treatment regimens despite no progression in extracranial lesions. Given that there is a dissociation in terms of response to erlotinib between brain and extracranial sites, we intend to conduct this pilot study to determine whether the continuation of erlotinib treatment can prolong the progression free interval of extracranial lesions as long as cranial lesion is controlled separately by conventional treatment modalities such as surgical resection, stereotactic radiosurgery, and whole brain radiotherapy.

The Continuation of Erlotinib

The Continuation of Erlotinib Treatment in Non-small Cell Lung Cancer Patients Whose Brain Lesion is the Only Site of Progression : Pilot Study

Samsung Medical Center

Myungju Ahn Ph.D., M.D.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer	NCT00466089	Carcinoma, Non-...	Erlotinib (Tarc...	18 Years -	Hospital of Navarra
The Continuation of Erlotinib	NCT01130779	Non-small Cell ...	Erlotinib (TARC...	18 Years -	Samsung Medical Center
Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer	NCT00466089	Carcinoma, Non-...	Erlotinib (Tarc...	18 Years -	Hospital of Navarra

Spots Global Cancer Trial Database for erlotinib (tarceva®)